116 related articles for article (PubMed ID: 12115833)
1. Nasal administration of low molecular weight heparin.
Arnold J; Ahsan F; Meezan E; Pillion DJ
J Pharm Sci; 2002 Jul; 91(7):1707-14. PubMed ID: 12115833
[TBL] [Abstract][Full Text] [Related]
2. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin.
Yang T; Arnold JJ; Ahsan F
J Drug Target; 2005 Jan; 13(1):29-38. PubMed ID: 15848952
[TBL] [Abstract][Full Text] [Related]
3. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin.
Mustafa F; Yang T; Khan MA; Ahsan F
J Pharm Sci; 2004 Mar; 93(3):675-83. PubMed ID: 14762906
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary delivery of low molecular weight heparins.
Yang T; Mustafa F; Bai S; Ahsan F
Pharm Res; 2004 Nov; 21(11):2009-16. PubMed ID: 15587922
[TBL] [Abstract][Full Text] [Related]
5. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.
Yang T; Hussain A; Bai S; Khalil IA; Harashima H; Ahsan F
J Control Release; 2006 Oct; 115(3):289-97. PubMed ID: 17023085
[TBL] [Abstract][Full Text] [Related]
6. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells.
Arnold JJ; Ahsan F; Meezan E; Pillion DJ
J Pharm Sci; 2004 Sep; 93(9):2205-13. PubMed ID: 15295781
[TBL] [Abstract][Full Text] [Related]
7. [Oral cavity delivery system of unfractionated and low molecular weight heparin].
Li D; Hou HM
Yao Xue Xue Bao; 2010 Oct; 45(10):1317-21. PubMed ID: 21348313
[TBL] [Abstract][Full Text] [Related]
8. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats.
Yang T; Mustafa F; Ahsan F
J Pharm Pharmacol; 2004 Jan; 56(1):53-60. PubMed ID: 14980001
[TBL] [Abstract][Full Text] [Related]
9. Intestinal absorption of low molecular weight heparin in animals and human subjects.
Nissan A; Ziv E; Kidron M; Bar-On H; Friedman G; Hyam E; Eldor A
Haemostasis; 2000; 30(5):225-32. PubMed ID: 11251329
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.
Yang T; Hussain A; Paulson J; Abbruscato TJ; Ahsan F
Pharm Res; 2004 Jul; 21(7):1127-36. PubMed ID: 15290851
[TBL] [Abstract][Full Text] [Related]
11. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats.
Mori S; Matsuura A; Rama Prasad YV; Takada K
Biol Pharm Bull; 2004 Mar; 27(3):418-21. PubMed ID: 14993814
[TBL] [Abstract][Full Text] [Related]
12. In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer.
Rama Prasad YV; Minamimoto T; Yoshikawa Y; Shibata N; Mori S; Matsuura A; Takada K
Int J Pharm; 2004 Mar; 271(1-2):225-32. PubMed ID: 15129989
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies.
Ito Y; Kusawake T; Prasad YV; Sugioka N; Shibata N; Takada K
Int J Pharm; 2006 Jul; 317(2):114-9. PubMed ID: 16631328
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
16. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside.
Arnold JJ; Fyrberg MD; Meezan E; Pillion DJ
J Pharm Sci; 2010 Apr; 99(4):1912-20. PubMed ID: 19894270
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
18. N-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules.
Thanou M; Henderson S; Kydonieus A; Elson C
J Control Release; 2007 Feb; 117(2):171-8. PubMed ID: 17184870
[TBL] [Abstract][Full Text] [Related]
19. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats.
Ahsan F; Arnold J; Meezan E; Pillion DJ
Pharm Res; 2001 Dec; 18(12):1742-6. PubMed ID: 11785695
[TBL] [Abstract][Full Text] [Related]
20. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
